Publix recalled Greenwise baby food pouches due to elevated lead levels. What to know
Check your shelves: Publix recalled one of its Greenwise baby food pouches due to the potential of elevated levels of lead contamination.
The Florida-based grocery store chain initiated a voluntary recall on May 9 for GreenWise Pear, Kiwi, Spinach & Pea Baby Food, from Bowman Andros LLC, a fruit processing factory in Virginia.
Even low levels of lead have been shown to affect learning and the ability to pay attention, according to the Centers for Disease Control and Prevention. Most children exposed to lead have no obvious immediate symptoms and may need a blood lead test.
'As part of our commitment to food safety, potentially impacted products have been removed from all store shelves,' said Publix Director of Communications Maria Brous in a release. 'To date, there have been no reported cases of illness."
The recall comes just under a month after Target recalled one of its own store-brand baby food products due to elevated lead levels. The national chain recalled 26,500 units of Good & Gather baby Pea, Zucchini, Kale & Thyme Vegetable Purèe from Miami-based Fruselva USA.
Food safety: FDA suspends food safety quality checks. How to protect yourself from salmonella, listeria
GreenWise Pear, Kiwi, Spinach & Pea Baby Food, 4 oz.
The items have a GTIN number of 41415-00901 and a "Best If" date of 11/01/2025.
Stop using it immediately. If you suspect your child has been exposed to lead, talk to their healthcare provider.
Consumers who have purchased the product in question may return the product to their local store for a full refund. Publix customers with additional questions may call the customer care department at 800-242-1227 or visit publix.com.
This article originally appeared on The Daytona Beach News-Journal: Publix baby food recall: Elevated Greenwise lead levels found
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
6 hours ago
- Miami Herald
Meth makes comeback in Minnesota in more dangerous and record ways
A subtle shift was happening among clients at the north Minneapolis community drop-in center. For years, people seeking substance abuse services at Anything Helps reported using just one drug of choice. Recently, staff noticed more and more users had expanded their appetite, preferring a combination of drugs at once versus 'picking a lane.' The polysubstance abuse among their regulars soon evolved almost exclusively to one pairing of drugs in the majority of their clients: fentanyl and methamphetamine. 'That's pretty new,' according to Brian Warden, the nonprofit's harm reduction director. 'That's something we traditionally see in cities like Denver, San Francisco or Seattle. That's not something we've really seen here.' To Warden, the change in the clientele's drug use pattern could stem from a number of reasons, including a correlation with a rise in homelessness in Minneapolis. But undoubtedly, he said, the phenomenon can be explained in part by the recent surge of methamphetamine in Minnesota. As the deadly fentanyl crisis demanded the state's attention post-pandemic, another was building with methamphetamine. The stimulant, long supreme in the underbelly of Minnesota's drug scene, is flooding the state - with a more dangerous dosage than meth of the past. 'The numbers are just a ridiculous amount of meth ... it just hasn't gotten enough publicity,' said Rafael Mattei, acting special agent in charge of the U.S. Drug Enforcement Administration's division over Minnesota. The meth surge in Minnesota came just as the street fentanyl crisis showed signs of easing. U.S. opioid overdose deaths plummeted 41% in 2024, according to the Centers for Disease Control and Prevention, and fatal overdoses of all kinds fell 27%. In Minnesota, preliminary data from the Minnesota Department of Health showed an 8% drop in overall overdose deaths from 2022 to 2023. But meth 'has never gone away,' Mattei said. No longer homemade in makeshift labs, meth is being churned out of Mexican super labs by cartels that cashed in on the lack of supply and cheaper production costs. And its price has plummeted, becoming a more lucrative option for dealers. Ken Sass, statewide drug and gang coordinator for the Minnesota Department of Public Safety, recalled a pound of meth costing $3,000 to $5,000 around 15 years ago, during his tenure as a federal drug agent. Now, he estimates, the price has fallen below $1,000. The drug makes its way to Minnesota most often by snaking up the Interstate 35 corridor to be sold in droves or continue into neighboring states. Last year, federal officials announced they had busted 'one of the largest and most prolific drug organizations' in Minnesota's history following the arrest of a Twin Cities man accused of helping push a historic amount of meth and other substances from Mexico. Federal prosecutors allege Clinton Ward made ties with two of Mexico's most notorious drug cartels and funneled the substance across the border via shipping containers, private vehicles and semitrailers before breaking the drug down into smaller quantities, then delivering it to Minnesota. The U.S. Attorney's Office charged Ward under the rare 'kingpin' statute, along with 14 others in the conspiracy case that led to the seizure of 1,600 pounds of methamphetamine, 4 kilograms of cocaine, 2 kilograms of fentanyl and 30,000 counterfeit fentanyl pills. Federal officials described the bust as a success for having disrupted a major pipeline of illegal drugs in Minnesota. Yet methamphetamine is continuing to pour into Minnesota with no sign of slowing down, data from the DEA indicates. Last year, the amount of methamphetamine seized by federal agents in Minnesota increased 142%, totaling 2,080 pounds, compared with the roughly 860 pounds of meth seized in 2023. The numbers do not include drugs seized by state, local or tribal law enforcement. Federal drug agents are on track to outpace the amount of meth seized last year. They've seen a 25% increase in the amount of meth seized from January to April 2025, compared with the same time last year. More readily available meth, Sass said, 'leads to more addiction and probably a broadening market as well.' And although meth may not be as lethal as fentanyl, the drug today poses its own dangers. The meth from Mexican super labs holds higher potency, resulting in a more dangerous and addictive concoction than the meth sold in the 1990s and early 2000s. After federal legislation in 2005 cracked down on the commercial sale of products containing precursor chemicals to make meth, such as pseudoephedrine in the decongestant Sudafed, cartels pursued the chemicals overseas and became bulk buyers. The product is then cut with other hazardous materials to bring maximum profit. Users deep in the throes of meth addiction can stay awake for days, leading to paranoia and hallucinations. A hallmark sign of meth addiction is wounds on a user's skin caused by incessant scratching. People who experience withdrawals may resort to theft, robbery or other crimes to obtain money for another hit. The elevated potency can only worsen symptoms, which carry ripple effects into communities. 'Their health, their mental health, their relationships, medical conditions that arise from addiction and all the personal problems that would come from [addiction] ... they relay that to the relationships with their family,' Sass said. In some cases, law enforcement and treatment providers are seeing fentanyl added to methamphetamine. Though the risk of dying from a meth overdose is much lower than that of fentanyl, which has a deadly dose that can fit on the tip of a pencil, the drug takes its toll 'little by little.' 'There is no accident here,' Warden said, saying of the adulteration of fentanyl with meth, 'I've never seen anything like that before.' Mattei likened the difference between the meth on the streets today compared with meth of the past as that of whiskey versus beer. 'They were making beer first,' Mattei said. 'Now the meth that's out there is kind of like higher-proof alcohol. So you need less to feel.' Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
The Hill
12 hours ago
- The Hill
Lyme-disease isn't the only tick-borne threat. Doctors warn these other diseases are spreading
(NEXSTAR) – You've likely heard public health officials' repeated pleas to check yourself, your kids and your pets for tick bites, which can spread serious diseases. While Lyme disease gets the most attention – and affects the most people – there are other tick-borne bacteria and diseases that have also been found spreading in the U.S. Just last month, Connecticut researchers said they identified the first case of a longhorned tick infected with a pathogen called ehrlichia chaffeensis. Infections can give people fever chills, headaches, muscle aches and stomach issues. 'We also worry about a parasite called Babesia, which causes a disease called Babesiosis,' said Nicole Baumgarth, a professor of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, in a recent briefing on tick-borne illnesses. The same ticks that carry the bacteria that cause Lyme disease can carry this parasite, which then infects people's red blood cells, causing anemia and other 'very serious consequences,' Baumgarth said. Some people infected by the parasite may feel flu-like symptoms, explains the Centers for Disease Control and Prevention, while others may have no symptoms at all. That's a problem if people live with the parasite and then donate their infected blood, which can cause harm to the people who receive it as a transfusion. Baumgarth also warned of viruses that can be spread by ticks, such as tick-borne encephalitis. It's an infection that can cause inflammation of the brain and spinal cord. It's a bigger problem in Europe than in the U.S., she said, but here we have Heartland virus and Powassan virus to contend with. 'Both viruses are still very rare, but we have seen our first case of Heartland virus in Maryland last year, and the fact that we are now seeing these virus infections in areas that we haven't seen them before, it probably indicates the tip of the iceberg,' said Baumgarth. Because these viruses are rarer, and their symptoms can be non-specific, doctors don't usually think to test for them, Baumgarth explained. Many cases of Heartland and Powassan virus could be left uncounted as a result. 'So it would be rare that we diagnose it because we are not looking hard enough for it right now,' she said. Both viruses can present with generic first symptoms like fever, headache and vomiting, but can cause serious illness if left unchecked. Powassan virus could lead to seizures, loss of coordination and confusion in severe cases where the brain and spinal cord are impacted. Yet another concern is the tick that can cause people to become allergic to red meat if they're bitten. It's called alpha-gal syndrome and is caused by bites from the Lone Star tick, first identified in Texas. However, this type of tick is 'very aggressively' moving north and becoming a problem in other regions of the country, according to Baumgarth. Some of these rare viruses don't have a treatment or cure, so prevention is what's most important, the CDC says. You should avoid ticks by wearing long sleeves and pants in bushy and wooded areas, using bug repellent, and doing a thorough tick check after spending time outside.
